Carcinoma in Situ of the Bladder
📧 Sign up to get email alerts when something new happens for Carcinoma in Situ of the Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer [Phase 3]
Phase 3 trial evaluating intravesical nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy for high-grade BCG…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC [Phase 2]
Phase 2 clinical trial evaluating intravesical gemcitabine and docetaxel for high-risk, BCG-unresponsive non-muscle-invasive bladder cancer;…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) [Phase 2]
A Phase 2 study of Intismeran Autogene (V940) in combination with BCG for bladder cancer is currently recruiting, targeting non-muscle-invas…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial [Phase 1, Phase 2]
The INVITE trial is investigating in-home intravesical chemotherapy for non-muscle invasive bladder cancer and is currently recruiting for P…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer [Phase 3]
Phase 3 trial update assessing intravesical TARA-002 versus investigator's choice intravesical chemotherapy for BCG-naïve high-grade non-mus…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve [Phase 1, Phase 2]
A Phase 1/2 study (LEGEND Study: EG-70) is recruiting to evaluate EG-70 in non-muscle invasive bladder cancer, including patients with carci…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients [NA]
A clinical trial update describing Hyperthermic Intravesical Chemotherapy (HIVEC) for high-grade non-muscle invasive bladder cancer that is …
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study [Phase 2]
This update describes an open-label, randomized Phase 2 trial evaluating toripalimab with or without sequential intravesical gemcitabine-mit…